Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05854498

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Led by University of Wisconsin, Madison · Updated on 2026-04-02

50

Participants Needed

1

Research Sites

246 weeks

Total Duration

On this page

Sponsors

U

University of Wisconsin, Madison

Lead Sponsor

I

Ipsen

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.

CONDITIONS

Official Title

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be 18 years of age or older
  • Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1
  • Histologically or cytologically confirmed colorectal adenocarcinoma that is metastatic or unresectable
  • Cancer must be mismatch repair proficient
  • Prior treatment with 5-fluorouracil, oxaliplatin, and irinotecan containing regimens
  • If RAS wild-type, prior anti-EGFR therapy with cetuximab or panitumumab
  • If RAS wild-type and HER2 positive, prior HER2 targeted therapy
Not Eligible

You will not qualify if you...

  • Uncontrolled concurrent medical illness preventing completion of planned therapy
  • Presence of BRAF V600 mutations in cancer
  • Use of strong inducers or inhibitors of CYP3A4 within 2 weeks before starting therapy
  • Mismatch repair deficient or microsatellite instability high cancers
  • Prior treatment with TAS102

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, United States, 52792

Actively Recruiting

Loading map...

Research Team

C

Cancer Connect

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here